Trials / Active Not Recruiting
Active Not RecruitingNCT04669197
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- HonorHealth Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
Conditions
- Untreated Resectable Pancreatic Adenocarcinoma
- Borderline Resectable Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel protein bound | combination therapy |
| DRUG | Gemcitabine | combination therapy |
| DRUG | Cisplatin | combination therapy |
| DRUG | Hydroxychloroquine | combination therapy |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2024-02-21
- Completion
- 2025-12-30
- First posted
- 2020-12-16
- Last updated
- 2025-08-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04669197. Inclusion in this directory is not an endorsement.